Book Value per Share: inmunebio.com (INMB)

Graphic logo of INmune Bio, Inc. (INMB)

INmune Bio, Inc. (INMB) minimizes biotech risks by developing treatments for cancer and dementia through immune activation. Disciplined management effectively allocates capital toward platform validation. The BVPS trend helps assess the value of net assets, where the indicator is fixed at 0.76. The company's advantage is the innovative XPro, which treats neuroinflammation in Alzheimer's disease while preserving the overall immune response.

INmune Bio Inc (INMB): Share Book Value from 07/04/2022 to 10/27/2026

inmunebio.com - analytical breakdowns and key metrics (INMB)

- price and consensus price forecast:
Price Chart INmune Bio Corp|INMB - Consensus Target
- market capitalization data:
Market Capitalization INmune Bio, Inc.|INMB - Total Company Value
- book capitalization data:
Net Assets per Single Share INmune Bio|INMB - Net Asset Value|Market Capitalization to Book Value Ratio inmunebio.com|INMB - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital INmune Bio, Inc.|INMB - Long-Term Debt to Capital|Short-Term Debt to Equity INmune Bio|INMB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio INmune Bio, Inc.
Fundamental company valuation:INmune Bio Corp - INMB
Manufactured products of INmune Bio

INmune Bio, Inc. (INMB) is creating long-term capitalization potential through its proprietary platforms for the development of innovative Alzheimer's disease and oncology therapies. This chart of historical book value visualizes the difference between total assets and liabilities per share, allowing investors to assess the real value of net assets and determine the extent to which the asset is overvalued relative to its tangible fundamentals.

Competitors of INmune Bio, Inc. (INMB)

ARGX: Net Assets per Single Share|BNTX - Accounting Value per Share|Abivax Corp (ABVX) - Book Value per Share|ADMA (admabiologics.com) - Net Assets per Single Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Kiniksa Pharmaceuticals Ltd (KNSA) - Book Value per Share|Accounting Value of a Share Grifols Biemat (GRFS)|Book Value per Share ADPT (Adaptive Biotechnologies)|celldex.com - Book Value per Share|Net Assets per Single Share Aurinia Pharmaceuticals Inc. (AUPH)|BCRX: Accounting Value of a Share|VERA (Vera Pharma) - Net Assets per Single Share|Dianthus Corp (DNTH) - Accounting Value per Share|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp (ABCL)|Tourmaline Bio (TRML) - Accounting Value per Share|Accounting Value of a Share Precigen Inc (PGEN)|Book Value per Share PHAR|Nektar Corp - Net Assets per Share|UPB: Net Assets per Single Share|ZBIO: Accounting Value per Share|IMNM (Immunome) - Net Assets per Single Share|Accounting Value per Share Gossamer Bio Inc|KALV (KalVista Pharmaceuticals Inc) - Accounting Value per Share|Book Value per Share SEPN|Net Assets per Single Share Pieris Pharmaceuticals PVLA|Equity per Share savarapharma.com (SVRA)|RIGL: Book Value per Share|Net Asset Value per Share AnaptysBio Inc ANAB|Book Value per Share ATXS (Astria Pharma)|ENGN: Net Assets per Share|Net Assets per Single Share RAPT Therapeutics, Inc.|JBIO (Aerovate Therapeutics) - Equity per Share|Net Assets per Single Share ACRS|Accounting Value per Share Kyverna Therapeutics Inc. (KYTX)|Accounting Value per Share TLSA|Book Value per Share CABA (Cabaletta Bio Inc)|VTYX - Net Assets per Single Share|Equity per Share theratech.com THTX|AVTX (Avalo Therapeutics) - Book Value per Share|Eledon Pharmaceuticals Inc. (ELDN) - Net Asset Value per Share|Accounting Value per Share Agenus Inc AGEN|Climb Bio, Inc (CLYM) - Accounting Value of a Share|Book Value per Share Zura Bio Limited|Net Assets per Single Share atyrpharma.com|ADAG (Adagene) - Book Value per Share|Net Assets per Share IMA (ikenaoncology.com)|STTK: Net Assets per Single Share|EQ - Net Asset Value per Share|Accounting Value per Share Connect Pharma (CNTB)|IMUX - Accounting Value of a Share|atarabio.com - Book Value per Share|IFRX (InflaRx) - Net Assets per Share|Net Assets per Single Share X4 Pharma (XFOR)|Equity per Share Adicet|Book Value per Share CELU (Celularity Inc.)|Accounting Value per Share barinthusbio.com BRNS|Accounting Value per Share KZR|Net Assets per Share SAB Biotherapeutics Inc. SABS|Book Value per Share AKTX (Akari Therapeutics plc)|ENLV: Net Assets per Share|Net Assets per Single Share q32bio.com|GOVX (geovax.com) - Equity per Share|Net Assets per Single Share EDSA|Accounting Value per Share iBio Inc|Book Value per Share Carisma Therapeutics (CARM)|Net Assets per Single Share XTLB (XTL Bio)|Bolt Biotherapeutics, Inc. (BOLT) - Net Assets per Single Share|Share Book Value HCW Biologics, Inc. HCWB|Book Value per Share Aptevo (APVO)|AIM - Accounting Value of a Share|ADTX: Book Value per Share|GRI (GRI Bio Corporation) - Book Value per Share|XRTX - Net Assets per Single Share|Accounting Value of a Share HIND|Net Assets per Single Share REVB (Revelation Biosciences, Inc.)|Accounting Value per Share Indaptus Therapeutics Inc (INDP)|Book Value per Share SCNI (Scinai)|CALI - Book Value per Share|Accounting Value per Share Affimed Therapeutics (AFMD)|ALLK - Accounting Value of a Share|hookipapharma.com - Book Value per Share|IGMS (IGM Biosciences) - Net Assets per Share|Net Assets per Single Share ITOS|Accounting Value per Share OCEA|Net Assets per Single Share TCBP (TC Biopharm)|Accounting Value per Share thirdharmonicbio.com THRD